Investor Presentation Q1-Q3 2020

63 Investor presentation First nine months of 2020 Solid commercial execution is driving 13% NorditropinⓇ sales growth in the first nine months of 2020 Historic reported sales for NorditropinⓇ DKK 40% billion 8% 14% -22% 7% 2% 13% 9 30% 6 3 20% 10% NorditropinⓇ value leadership maintained despite increasing competition 35.3% 0 0% 2015 2016 2017 2018 2019 9M 2020 Aug 2015 Novo Nordisk ⚫Pfizer Aug 2020 Norditropin Growth at CER Eli Lilly Roche Merck Kgaa -Other Sandoz Note: Company reported sales; CER: Constant exchange rates Note: IQVIA, MAT value DKK, Aug 2020 Novo NordiskⓇ Continue frequent launches with new indications and device upgrades Device portfolio norditropin simpleXx somatropin (rDNA origin) injection norditropin flexpro somatropin (rDNA origin) injection norditropin nordilet somatropin (rDNA origin) injection norditropin nordiflex® somatropin (rDNA origin) injection norditropin somatropin (rDNA origin) injection Noonan syndrome, EU device upgrades Current launches Towards 2022 16 + 30

View entire presentation